Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-COVER
2005-001999-12Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary efficacy endpoint. Started Dec 2005; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2005-001999-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001999-12.